Shivom

Shivom

Shivom are raising money via their ICO to build a genomic and health data hub to allow them to be able to supply personalized medicine.

7.4
Token Sale ended
10 May, 2018
ETH 13,121
of
ETH 15,000 (87%)

Shivom Info

Ticker:
OMX
Token Type
ERC20
Fundraising Goal:
ETH 15,000
Received
ETH 13,121 (87%)
Price
1 OMX = 0.0001400 ETH
Sold on Pre-sale
33%
Total Tokens
3,000,000,000
Token Available for Sale
990,000,000
Whitepaper
Yes
KYC
Yes
Country
Isle of Man
Industry
Medical
Blocked Countries
USA
Accepting
ETH, BTC, USD

Pros & Cons

  • Very experienced team who have a proven track record
  • Robust whitepaper and roadmap
  • Quite a reasonable conversion rate to Ethereum
  • There is a gap in the market for such a concept
  • Soft cap goal should be quickly achieved
  • Large investment may be required
  • High tech project and concept
  • Could require time to develop
  • Limited appeal for small investors
  • High targeted market place and business sector

Features

Shivom are raising money via their ICO to build a genomic and health data hub to allow them to be able to supply personalized medicine.

Overview

Shivom have put together an amazing concept, and one that will no doubt take some time to achieve, but when it does it could possibly completely revolutionize the medical world.

What they are planning on doing, and the reason why they are looking for funding via their ICO is to use DNA donors to allow their medical team to work on tailored drugs that will help cure or alleviate the symptoms of a range of different diseases.

Now, for anyone who is looking to invest in their initial coin offering, I would strongly suggest that you read through their white paper and spend some time on their website to make sure you know the way they are aiming to progress after achieving their funding goal.

There are always going to be risks associated with any type of drug and medical related investment opportunities, and I do want you to be aware of those risks, but also get a true and full understanding of how the company will be run after reaching their funding goals.

Team

Members

  • Dr. Axel Schumacher (Co-Founder & CEO)
  • Gourish Singla (Co-Founder & COO)
  • Sally Eaves (Co-Founder & CMO)
  • Henry Ines (Chief Innovation Officer)

Conclusion

You do have to hand it to the team at Shivom, if they do manage to achieve their funding goal and do everything as laid out on their white paper and road map, this is going to be one of the much more interesting ICO’s to invest in.

However, just be prepared for the fact that often when you are investing in medical related companies, businesses and concepts, that it could take some time for you to see some or even any returns on your investments.

Therefore, this is probably going to be an ICO that is going to appeal to investors who are prepared to invest their money in the hope of long term as opposed to short term returns, so keep that in mind and only invest in their tokens if you are completely satisfied that is something you are prepared to do.

CoinTrust ICO review Panel

On-going ICOs